Complexa Inc. landed a $13 million series B and new investor Jafco Life Science Investment, a unit of Tokyo-based private equity firm Jafco Co. Ltd., to advance development of two formulations of its lead compound CXA-10. The Pittsburgh-based company has an intravenous formulation of CXA-10 in a phase I study to treat contrast imaging dye-induced nephropathy (CIN), a form of acute kidney injury (AKI), as the compound's proof-of-concept indication.